A detailed history of Price T Rowe Associates Inc transactions in Annexon, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,094,472 shares of ANNX stock, worth $8.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,094,472
Previous 1,323,704 17.32%
Holding current value
$8.18 Million
Previous $9.49 Million 43.49%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.33 - $6.79 $992,574 - $1.56 Million
-229,232 Reduced 17.32%
1,094,472 $5.36 Million
Q1 2024

May 15, 2024

BUY
$4.03 - $7.81 $5.28 Million - $10.2 Million
1,311,195 Added 10482.01%
1,323,704 $9.49 Million
Q4 2023

Feb 14, 2024

BUY
$1.63 - $4.63 $20,389 - $57,916
12,509 New
12,509 $57,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $4.06 $2.8 Million - $5.38 Million
-1,324,733 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.73 - $11.94 $4.24 Million - $18.5 Million
-1,551,934 Reduced 53.95%
1,324,733 $3.62 Million
Q4 2021

Feb 14, 2022

BUY
$11.49 - $22.0 $13.2 Million - $25.3 Million
1,151,996 Added 66.8%
2,876,667 $33.1 Million
Q3 2021

Nov 15, 2021

BUY
$16.35 - $23.4 $6.77 Million - $9.69 Million
414,187 Added 31.61%
1,724,671 $32.1 Million
Q2 2021

Aug 16, 2021

SELL
$17.81 - $27.48 $514,299 - $793,539
-28,877 Reduced 2.16%
1,310,484 $29.5 Million
Q1 2021

May 17, 2021

BUY
$22.0 - $35.01 $2.94 Million - $4.69 Million
133,858 Added 11.1%
1,339,361 $37.3 Million
Q4 2020

Feb 16, 2021

BUY
$20.81 - $30.55 $25.1 Million - $36.8 Million
1,205,503 New
1,205,503 $30.2 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $356M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.